HCM
ESPR

Highbridge Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Highbridge Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-77,100
Closed -$75.6K – 367
2023
Q3 		$75.6K Hold
77,100
– – ﹤0.01% 237
2023
Q2 		$107K Hold
77,100
– – ﹤0.01% 219
2023
Q1 		$123K Sell
77,100
-380,300
-83% -$1.96M ﹤0.01% 229
2022
Q4 		$2.85M Buy
+457,400
New +$3.27M 0.08% 209

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Highbridge Capital Management's ESPR Position: Q4 2025 in Review

Highbridge Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 254,265 shares — an estimated $674K sold.

Highbridge Capital Management first reported a position in ESPR in Q1 2015 and held it in 19 quarters. The position peaked at $8.75M in Q1 2015. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Highbridge Capital Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 254,265 Esperion Therapeutics shares in Q4 2025, an estimated $674K.
  • Highbridge Capital Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 19 quarters.
  • Highbridge Capital Management's Esperion Therapeutics position peaked at $8.75M in Q1 2015.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Highbridge Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.